Literature DB >> 31555865

Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome.

Keisuke Yano1, Tatsuru Kaji1,2, Shun Onishi1, Seiro Machigashira1, Taichiro Nagai1, Toshio Harumatsu1, Koji Yamada1, Waka Yamada1, Mitsuru Muto1, Kazuhiko Nakame1, Motoi Mukai1, Satoshi Ieiri3.   

Abstract

PURPOSE: Short bowel syndrome (SBS) patients require long-term parenteral nutrition following massive bowel resection, which causes intestinal failure-associated liver disease (IFALD). Previous reports have shown that glucagon-like peptide-2 (GLP-2) resulted in the bowel adaptation for SBS. The aim of this study was to evaluate the effect of GLP-2 for IFALD in a parenterally fed rat model.
METHODS: Using rat, a catheter was placed in the jugular vein, and 90% small bowel resection (SBR) was performed. Animals were divided into three groups: SBR and total parenteral nutrition (TPN) (SBS/TPN group), SBR and TPN plus GLP-2 at 1 µg/kg/h [SBS/TPN/GLP-2 (low) group], and SBR and TPN plus GLP-2 at 10 µg/kg/h [SBS/TPN/GLP-2 (high) group]. On day 13, the liver was harvested and analyzed by using nonalcoholic fatty liver disease (NAFLD) score.
RESULTS: Histologically, hepatic steatosis in the SBS/TPN group and SBS/TPN/GLP-2 (high) group was observed. Both steatosis and lobular inflammation score in the SBS/TPN/GLP-2 (low) group were significantly lower compared with those in the other two groups (p < 0.05). Active NAFLD score in the SBS/TPN/GLP-2 (low) group was significantly lower compared with that in the SBS/TPN/GLP-2 (high) group (p < 0.01).
CONCLUSION: Low-dose GLP-2 intravenous administration improves hepatic steatosis of IFALD following in an SBS parenterally fed rat model.

Entities:  

Keywords:  Glucagon-like peptide-2; IFALD; NAFLD; Short bowel syndrome; Steatosis; Total parenteral nutrition

Mesh:

Substances:

Year:  2019        PMID: 31555865     DOI: 10.1007/s00383-019-04560-8

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  15 in total

Review 1.  Short bowel syndrome in children: surgical and medical perspectives.

Authors:  Riccardo Coletta; Basem A Khalil; Antonino Morabito
Journal:  Semin Pediatr Surg       Date:  2014-09-04       Impact factor: 2.754

2.  Pivotal Role of TNF-α in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model.

Authors:  Satomi Kakino; Tsuyoshi Ohki; Hitomi Nakayama; Xiahong Yuan; Shuichi Otabe; Toshihiko Hashinaga; Nobuhiko Wada; Yayoi Kurita; Kayo Tanaka; Kento Hara; Eri Soejima; Yuji Tajiri; Kentaro Yamada
Journal:  Horm Metab Res       Date:  2017-09-18       Impact factor: 2.936

3.  GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice.

Authors:  Jennifer Taher; Christopher Baker; Danielle Alvares; Laraib Ijaz; Mahmood Hussain; Khosrow Adeli
Journal:  Endocrinology       Date:  2018-09-01       Impact factor: 4.736

Review 4.  ALX-0600 (NPS Allelix Corp).

Authors:  D L Sigalet
Journal:  Curr Opin Investig Drugs       Date:  2001-04

5.  The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat.

Authors:  Tatsuru Kaji; Hiroaki Tanaka; Jens J Holst; Heather Redstone; Laurie Wallace; Elaine de Heuval; David L Sigalet
Journal:  Eur J Pharmacol       Date:  2008-08-22       Impact factor: 4.432

6.  Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration.

Authors:  Noura El-Jamal; Edmone Erdual; Michel Neunlist; Dine Koriche; Caroline Dubuquoy; Francois Maggiotto; Julien Chevalier; Dominique Berrebi; Laurent Dubuquoy; Eric Boulanger; Antoine Cortot; Pierre Desreumaux
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-29       Impact factor: 4.052

Review 7.  Intestinal failure-associated liver disease: what do we know today?

Authors:  Deirdre A Kelly
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

8.  Glucagon-Like Peptide 2 Improves Cholestasis in Parenteral Nutrition--Associated Liver Disease.

Authors:  David W Lim; Paul W Wales; Jessica K Josephson; Patrick N Nation; Pamela R Wizzard; Consolato M Sergi; Catherine J Field; David L Sigalet; Justine M Turner
Journal:  JPEN J Parenter Enteral Nutr       Date:  2014-10-03       Impact factor: 4.016

9.  The protective and anti-inflammatory effects of glucagon-like peptide-2 in an experimental rat model of necrotizing enterocolitis.

Authors:  Kazuhiko Nakame; Tatsuru Kaji; Motoi Mukai; Shin Shinyama; Hiroshi Matsufuji
Journal:  Peptides       Date:  2015-11-10       Impact factor: 3.750

10.  GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting.

Authors:  Marc Schoeler; Thomas Klag; Judith Wendler; Simon Bernhard; Michael Adolph; Andreas Kirschniak; Martin Goetz; Nisar Malek; Jan Wehkamp
Journal:  Therap Adv Gastroenterol       Date:  2018-08-30       Impact factor: 4.409

View more
  5 in total

1.  The administration of hepatocyte growth factor prevents total parenteral nutrition-induced hepatocellular injury in a rat model.

Authors:  Makoto Matsukubo; Keisuke Yano; Tatsuru Kaji; Koshiro Sugita; Shun Onishi; Toshio Harumatsu; Ayaka Nagano; Mayu Matsui; Masakazu Murakami; Koji Yamada; Waka Yamada; Mitsuru Muto; Kotaro Kumagai; Akio Ido; Satoshi Ieiri
Journal:  Pediatr Surg Int       Date:  2021-01-03       Impact factor: 1.827

2.  Improvement in metabolic indices including thyroid hormones via enhanced absorption of nutrients by Teduglutide in short bowel syndrome.

Authors:  Ken C Oba; Sarah Exley; Udaya M Kabadi
Journal:  Int J Surg Case Rep       Date:  2022-05-01

3.  Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice.

Authors:  Shai Fuchs; Bernardo Yusta; Laurie L Baggio; Elodie M Varin; Dianne Matthews; Daniel J Drucker
Journal:  JCI Insight       Date:  2020-04-23

Review 4.  New insights into intestinal failure-associated liver disease in adults: A comprehensive review of the literature.

Authors:  Fotios S Fousekis; Ioannis V Mitselos; Dimitrios K Christodoulou
Journal:  Saudi J Gastroenterol       Date:  2021 Jan-Feb       Impact factor: 2.485

5.  The protective effects of hepatocyte growth factor on the intestinal mucosal atrophy induced by total parenteral nutrition in a rat model.

Authors:  Koshiro Sugita; Tatsuru Kaji; Keisuke Yano; Makoto Matsukubo; Ayaka Nagano; Mayu Matsui; Masakazu Murakami; Toshio Harumatsu; Shun Onishi; Koji Yamada; Waka Yamada; Mitsuru Muto; Kotaro Kumagai; Akio Ido; Satoshi Ieiri
Journal:  Pediatr Surg Int       Date:  2021-08-26       Impact factor: 1.827

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.